文献速递淋巴瘤造血干细胞移植与细胞治疗

嵌合抗原受体T细胞治疗失败并暴露于双特异性抗体后的异基因移植:可行性、安全性与生存结局

Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes.
PubMed 文献 · Br J Haematol · 2025-07-22

研究在大B细胞淋巴瘤CAR-T失败后回顾性分析35例异基因移植候选者,13例(37%)在缓解后接受移植,所有移植患者均植入且全部存活于完全缓解,未移植者中位总生存11.7个月、13例疾病相关死亡。

要点

  • 170例CAR-T治疗患者中83例疾病进展,69例(83%)开始挽救治疗,最常用格菲妥单抗38例(55%)。
  • 35例异基因移植候选者中13例(37%)达完全或部分缓解后接受移植,中位既往治疗线数5线。
  • 移植者全部植入,III-IV级急性移植物抗宿主病8%、中重度慢性移植物抗宿主病15%,中位随访18.4个月非复发死亡0%。

核心结论

  • 尽管既往接受过大量T细胞重定向治疗,对挽救方案有选择的缓解者进行异基因移植巩固可能获益,但样本量小。

研究设计与样本

  • 2019年至2025年,两家学术中心170例接受CAR-T治疗的大B细胞淋巴瘤患者中记录83例疾病进展,回顾性分析其中35例异基因移植候选者的结局。

主要发现

  • 83例疾病进展中69例(83%)开始挽救治疗,最常用格菲妥单抗38例(55%)。
  • 35例异基因移植候选者中13例(37%)在达完全或部分缓解后接受异基因移植,中位既往治疗线数5线。
  • 所有移植患者均植入,III-IV级急性移植物抗宿主病发生率为8%,中重度慢性移植物抗宿主病为15%。
  • 中位随访18.4个月,非复发死亡为0%,所有移植患者均存活于完全缓解。
  • 未移植的22例患者结局差,中位总生存11.7个月,疾病相关死亡13例(59%)。

局限性

  • 原文述样本量小(small cohort of patients)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical outcome after chimeric antigen receptor (CAR)-T-cell failure in large B-cell lymphoma (LBCL) is dismal. Allogeneic stem cell transplantation (alloSCT) represents a potentially curative salvage for relapsed/refractory LBCL, although concerns remain regarding its feasibility and safety in patients exposed to CAR-T and bispecific antibodies. Between 2019 and 2025, 83 disease progressions were documented among 170 LBCL patients treated with CAR-T in two academic centres; 69 (83%) started salvage treatment, the most frequent being glofitamab in 38 (55%); among those, we retrospectively analysed outcomes of 35 candidates for alloSCT consolidation. Ultimately, 13 (37%) underwent alloSCT after achieving complete (CR) or partial response. The median number of previous therapies was 5. All patients engrafted; grade III-IV acute graft-versus-host disease (GvHD) occurred in 8% and moderate-to-severe chronic GvHD in 15% of patients respectively. At 18.4-month median follow-up, non-relapse mortality was 0%; all allografted patients are alive in CR; conversely, the outcome of 22 patients not proceeding to transplant was poor, with a median overall survival of 11.7 months and 13 disease-related deaths (59%). Although in a small cohort of patients, our data highlight the potential benefit of alloSCT consolidation in selected responders to salvage regimens despite the extensive prior treatments with T-cell redirecting therapies.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Barone A, De Philippis C, Stella F, et al. Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes. Br J Haematol. 2025. PMID: 40695357. doi:10.1111/bjh.70010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。